NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...
Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...
Budget 2025 hopes to extend financial incentives to clinical research industry for developing cutting-edge therapies in India ...
The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...
Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...
A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for ...
GlobalData on MSN2d
Fortress doses first subject in Phase II CMV vaccine trialFortress Biotech, Helocyte have announced the dosing of the first subject in the trial of Triplex for individuals who are ...
New Delhi: Sun Pharma Labs has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback